Please assess the completion status of the following clinical trial:

Trial Title: Re-Evaluation of Tumor Samples From Women With Breast Cancer With the in Vitro Diagnostic Kit MammaTyperTM

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Invasive breast cancer verified in a histological biopsy~* Age 65 or younger~* Estrogen receptor (ER), PgR and HER2 expression have been determined~* No distant metastases present (M0)~* The patient provides a written informed consent for study participation~* The estimated risk of breast cancer recurrence is high (25% or higher within the first 5 years from the date of the diagnosis, over \>35% within the first 10 years from the diagnosis)~Exclusion Criteria:~* Patients with breast cancer with a special histological type (mucinous, papillary, medullary, or tubular type of breast cancer) when no metastases are present in the ipsilateral axillary lymph nodes~* The WHO performance status is moderate/poor, Z \>1~* The peripheral blood leukocyte count is less than 3.0 x 109/L, the blood granulocyte count is less than 1.5 x 109/L, or the blood thrombocyte count is less than 120 x 109/L~* Any physical or mental disorder that is considered to prohibit administration of chemotherapy~* Cardiac failure; severe cardiac arrythmia requiring regular medication

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MammaTyper™ (Type: EXPERIMENTAL): MammaTyper™ kit will be used tio assess tumor material of patients enrolled into the FinHer trial.

Based on this trial design, predict the completion outcome and termination type (if applicable).